Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 2019 Cantor Fitzgerald Global Healthcare Conference being held on October 2-4, 2019 at the InterContinental New York Barclay Hotel in New York City. Jan D’Alvise, Chief Executive Officer, is scheduled to present on Wednesday, October 2, 2019 at 7:45 a.m. Eastern Time with one-on-one meetings being held throughout the day.

About CaPre (omega-3 phospholipid)